- Trials with a EudraCT protocol (5)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (8)
5 result(s) found for: GV.
Displaying page 1 of 1.
EudraCT Number: 2007-002455-16 | Sponsor Protocol Number: LTGV550-PII-11/06 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Laboratoires Théa | |||||||||||||
Full Title: Efficacy and safety of GV 550 in acute adenoviral keratoconjunctivitis | |||||||||||||
Medical condition: acute adenoviral keratoconjunctivitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-020775-22 | Sponsor Protocol Number: IT2191002 | Start Date*: 2010-08-10 |
Sponsor Name:ClinTrio Ltd. | ||
Full Title: Assessment of myocardial viability using reduced doses of contrast agent (GV Via) | ||
Medical condition: Patients with a history of chronic myocardial infarction due to coronary artery disease and a successful LGE-CMR scan. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2004-001551-11 | Sponsor Protocol Number: Iloprost | Start Date*: 2004-09-22 |
Sponsor Name:Lund University Hospital | ||
Full Title: Behandling av förhöjt pulmonellt arteriellt tryck med inhalerad iloprost | ||
Medical condition: Nyfödda barn som är i behov av respiratorvård pga RDS, mekoniumaspiration eller primär lunghypertension | ||
Disease: | ||
Population Age: Preterm newborn infants, Newborns, Under 18 | Gender: Male, Female | |
Trial protocol: SE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2022-002471-11 | Sponsor Protocol Number: Leuprorelin-4002 | Start Date*: 2022-08-08 | |||||||||||
Sponsor Name:Takeda (China) International Trading Co., Ltd. | |||||||||||||
Full Title: An Open Label, Multicenter, Single-arm and Prospective Study to Assess the Efficacy and Safety of Leuprorelin 3M in the Treatment of Central Precocious Puberty (CPP) | |||||||||||||
Medical condition: Central Precocious Puberty | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-001713-39 | Sponsor Protocol Number: TCD601F201 | Start Date*: 2022-11-28 | |||||||||||
Sponsor Name:ITB-MED AB | |||||||||||||
Full Title: A 12-month, randomized, single-blind, placebo-controlled exposure-response study of TCD601 (siplizumab) in new onset type 1 diabetes patients (STRIDE) | |||||||||||||
Medical condition: New onset Type I Diabetes | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
